Edarbi - (40, 80 mg; Tablet, Oral)

Generic Name	Azilsartan Kamedoxomil	Innovator	Azurity (Arbor)
Dosage	40, 80 mg; Tablet, Oral	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Edarbi (azilsartan) is an angiotensin II receptor blocker (sometimes called an ARB). Azilsartan keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow. Edarbi is used to treat high blood pressure (hypertension).
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ ***	*** *, ****	*******	******** ************	******* *** **** *** *** ****
**** **** ****** ** ******* **	** \ **	*** **, ****	*******	****	***** ***-**** ***********
********	** \ **	*** **, ****	*******	****	***** ***-**** ***********

Chronology Of Events